These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19276284)

  • 21. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
    Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
    Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cisplatin enhances TRAIL-induced apoptosis in gastric cancer cells through clustering death receptor 4 into lipid rafts].
    Xu L; Qu XJ; Liu YP; Liu J; Zhang Y; Hou KZ; Jiang YH
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):484-8. PubMed ID: 22093622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
    Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
    Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S
    Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway.
    Vondálová Blanárová O; Jelínková I; Szöor A; Skender B; Soucek K; Horváth V; Vaculová A; Andera L; Sova P; Szöllosi J; Hofmanová J; Vereb G; Kozubík A
    Carcinogenesis; 2011 Jan; 32(1):42-51. PubMed ID: 21037225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5.
    Chen JJ; Mikelis CM; Zhang Y; Gutkind JS; Zhang B
    Oncotarget; 2013 Feb; 4(2):206-17. PubMed ID: 23470485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies.
    Duiker EW; Dijkers EC; Lambers Heerspink H; de Jong S; van der Zee AG; Jager PL; Kosterink JG; de Vries EG; Lub-de Hooge MN
    Br J Pharmacol; 2012 Apr; 165(7):2203-12. PubMed ID: 22014269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
    Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
    Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apoptosis-inducing effect of the DR5 monoclonal antibody, D-6, alone or in combination with cisplatin, on A2780 ovarian cancer cells.
    Jiang Q; Zhu H; Liang B; Huang Y; Li C
    Mol Med Rep; 2012 Aug; 6(2):316-20. PubMed ID: 22562097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
    van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
    BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [TRAIL impacts in growth and apoptosis of human ovarian carcinoma cell line SKOV3].
    Li CM; Peng ZL; Yin RT; Hu M
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Sep; 37(5):761-4. PubMed ID: 17037746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells.
    Su L; Liu G; Hao X; Zhong N; Zhong D; Liu X; Singhal S
    Eur J Cancer; 2011 Nov; 47(16):2471-8. PubMed ID: 21726997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
    Kim EH; Yoon MJ; Kim SU; Kwon TK; Sohn S; Choi KS
    Cancer Res; 2008 Jan; 68(1):266-75. PubMed ID: 18172319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
    Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
    Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.
    Horinaka M; Yoshida T; Nakata S; Shiraishi T; Tomosugi M; Yoshikawa S; Wakada M; Sakai T
    Cancer Sci; 2012 Feb; 103(2):282-7. PubMed ID: 22077238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
    Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.
    Reis CR; van der Sloot AM; Natoni A; Szegezdi E; Setroikromo R; Meijer M; Sjollema K; Stricher F; Cool RH; Samali A; Serrano L; Quax WJ
    Cell Death Dis; 2010 Oct; 1(10):e83. PubMed ID: 21368856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.
    Kendrick JE; Straughn JM; Oliver PG; Wang W; Nan L; Grizzle WE; Stockard CR; Alvarez RD; Buchsbaum DJ
    Gynecol Oncol; 2008 Mar; 108(3):591-7. PubMed ID: 18177927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.